Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platform

View ORCID ProfileBrian MacKenna, View ORCID ProfileNicholas A. Kennedy, Amir Mehkar, Anna Rowan, View ORCID ProfileJames Galloway, View ORCID ProfileKathryn E. Mansfield, View ORCID ProfileKatie Bechman, View ORCID ProfileJulian Matthewman, View ORCID ProfileMark Yates, View ORCID ProfileJeremy Brown, View ORCID ProfileAnna Schultze, View ORCID ProfileSam Norton, View ORCID ProfileAlex J. Walker, View ORCID ProfileCaroline E Morton, View ORCID ProfileDavid Harrison, View ORCID ProfileKrishnan Bhaskaran, View ORCID ProfileChristopher T. Rentsch, View ORCID ProfileElizabeth Williamson, View ORCID ProfileRichard Croker, View ORCID ProfileSeb Bacon, View ORCID ProfileGeorge Hickman, Tom Ward, View ORCID ProfileSimon Davy, Amelia Green, View ORCID ProfileLouis Fisher, William Hulme, View ORCID ProfileChris Bates, View ORCID ProfileHelen J. Curtis, View ORCID ProfileJohn Tazare, View ORCID ProfileRosalind M. Eggo, David Evans, Peter Inglesby, View ORCID ProfileJonathan Cockburn, View ORCID ProfileHelen I. McDonald, View ORCID ProfileLaurie A. Tomlinson, View ORCID ProfileRohini Mathur, View ORCID ProfileAngel YS Wong, Harriet Forbes, John Parry, Frank Hester, Sam Harper, Ian J. Douglas, View ORCID ProfileLiam Smeeth, View ORCID ProfileCharlie W Lees, View ORCID ProfileStephen JW Evans, View ORCID ProfileBen Goldacre, View ORCID ProfileCatherine Smith, View ORCID ProfileSinéad M. Langan
doi: https://doi.org/10.1101/2021.09.03.21262888
Brian MacKenna
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Brian MacKenna
Nicholas A. Kennedy
2Department of Gastroenterology, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK
3IBD Research Group, University of Exeter, Exeter, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicholas A. Kennedy
Amir Mehkar
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Rowan
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Galloway
4Centre of Rheumatic Diseases, King’s College London, Denmark Hill, London SE5 9RS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James Galloway
Kathryn E. Mansfield
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kathryn E. Mansfield
Katie Bechman
4Centre of Rheumatic Diseases, King’s College London, Denmark Hill, London SE5 9RS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Katie Bechman
Julian Matthewman
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Julian Matthewman
Mark Yates
4Centre of Rheumatic Diseases, King’s College London, Denmark Hill, London SE5 9RS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark Yates
Jeremy Brown
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jeremy Brown
Anna Schultze
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna Schultze
Sam Norton
4Centre of Rheumatic Diseases, King’s College London, Denmark Hill, London SE5 9RS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sam Norton
Alex J. Walker
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alex J. Walker
Caroline E Morton
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Caroline E Morton
David Harrison
7Intensive Care National Audit & Research Centre (ICNARC), High Holborn, London WC1V 6AZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Harrison
Krishnan Bhaskaran
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Krishnan Bhaskaran
Christopher T. Rentsch
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher T. Rentsch
Elizabeth Williamson
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elizabeth Williamson
Richard Croker
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard Croker
Seb Bacon
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Seb Bacon
George Hickman
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for George Hickman
Tom Ward
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Davy
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Simon Davy
Amelia Green
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis Fisher
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Louis Fisher
William Hulme
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Bates
6TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chris Bates
Helen J. Curtis
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Helen J. Curtis
John Tazare
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for John Tazare
Rosalind M. Eggo
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rosalind M. Eggo
David Evans
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Inglesby
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Cockburn
6TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jonathan Cockburn
Helen I. McDonald
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Helen I. McDonald
Laurie A. Tomlinson
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laurie A. Tomlinson
Rohini Mathur
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rohini Mathur
Angel YS Wong
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angel YS Wong
Harriet Forbes
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Parry
6TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Hester
6TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sam Harper
6TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian J. Douglas
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liam Smeeth
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Liam Smeeth
Charlie W Lees
8Centre for Genomics and Experimental Medicine, University of Edinburgh Western General Hospital, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Charlie W Lees
Stephen JW Evans
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephen JW Evans
Ben Goldacre
1The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ben Goldacre
Catherine Smith
9St John’s Institute of Dermatology, Guys and St Thomas’ NHS Foundation Trust and Kings College London SE1 9RT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Catherine Smith
Sinéad M. Langan
5London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT
9St John’s Institute of Dermatology, Guys and St Thomas’ NHS Foundation Trust and Kings College London SE1 9RT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sinéad M. Langan
  • For correspondence: Sinead.langan@lshtm.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background It is unclear if people with immune-mediated inflammatory diseases (IMIDs) (joint, bowel and skin) and on immune modifying therapy have increased risk of serious COVID-19 outcomes.

Methods With the approval of NHS England we conducted a cohort study, using OpenSAFELY, analysingroutinely-collected primary care data linked to hospital admission, death and previously unavailable hospital prescription data. We used Cox regression (adjusting for confounders) to estimate hazard ratios (HR) comparing risk of COVID-19-death, death/critical care admission, and hospitalisation (March to September 2020) in: 1) people with IMIDs compared to the general population; and 2) people with IMIDs on targeted immune modifying drugs (e.g., biologics) compared to standard systemic treatment (e.g., methotrexate).

Findings We identified 17,672,065 adults; of 1,163,438 (7%) with IMIDs, 19,119 people received targeted immune modifying drugs, and 200,813 received standard systemics. We saw evidence of increased COVID-19-death (HR 1.23, 95%CI 1.20, 1.27), and COVID-19 hospitalisation (HR 1.32, 95%CI 1.29, 1.35) in individuals with IMIDs overall compared to individuals without IMIDs of the same age, sex, deprivation and smoking status. We saw no evidence of increased COVID-19 deaths with targeted compared to standard systemic treatments (HR 1.03, 95%CI 0.80, 1.33). There was no evidence of increased COVID-19-related death in those prescribed TNF inhibitors, IL-12/23, IL7, IL-6 or JAK inhibitors compared to standard systemics. Rituximab was associated with increased COVID-19 death (HR 1.68, 95%CI 1.11, 2.56); however, this finding may relate to confounding.

Interpretation COVID-19 death and hospitalisation was higher in people with IMIDs. We saw no increased risk of adverse COVID-19 outcomes in those on most targeted immune modifying drugs for IMIDs compared to standard systemics.

Evidence before this study We searched PubMed on May 19th, 2021, using the terms “COVID-19”, “SARS-CoV-2” and “rheumatoid arthritis”, “psoriatic arthritis” “ankylosing spondylitis”, “Crohn’s disease” “ulcerative colitis” “hidradenitis suppurativa” and “psoriasis”, to identify primary research articles examining severe COVID-19 outcome risk in individuals with immune-mediated inflammatory diseases (IMIDs) and those on immune modifying therapy. The studies identified (including matched cohort studies and studies in disease-specific registries) were limited by small sample sizes and number of outcomes. Most studies did not show a signal of increased adverse COVID-19 outcomes in those on targeted therapies, with the exception of rituximab. Additionally, disease-specific registries are subject to selection bias and lack denominator populations.

Added value of the study In our large population-based study of 17 million individuals, including 1 million people with IMIDs and just under 200,000 receiving immune modifying medications, we saw evidence that people with IMIDs had an increased risk of COVID-19-related death compared to the general population after adjusting for potential confounders (age, sex, deprivation, smoking status) (HR 1.23, 95%CI 1.20, 1.27). We saw differences by IMID type, with COVID-19-related death being increased by the most in people with inflammatory joint disease (HR 1.47, 95%CI 1.40, 1.54). We also saw some evidence that those with IMIDs were more likely, compared to the general population, to have COVID-19-related critical care admission/death (HR 1.24, 95%CI 1.21, 1.28) and hospitalisation (HR 1.32, 95%CI 1.29, 1.35).

Compared to people with IMIDs taking standard systemics, we saw no evidence of differences in severe COVID-19-related outcomes with TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-6 inhibitors and JAK inhibitors. However, there was some evidence that rituximab was associated with an increased risk of COVID-19-related death (HR 1.68, 95%CI 1.11, 2.56) and death/critical care admission (HR 1.92, 95%CI 1.31, 2.81). We also saw evidence of an increase in COVID-19-related hospital admissions in people prescribed rituximab (HR 1.59, 95%CI 1.16, 2.18) or JAK inhibition (HR 1.81, 95%CI 1.09, 3.01) compared to those on standard systemics, although this could be related to worse underlying health rather than the drugs themselves, and numbers of events were small.

This is the first study to our knowledge to use high-cost drug data on medicines supplied by hospitals at a national scale in England (to identify targeted therapies). The availability of these data fills an important gap in the medication record of those with more specialist conditions treated by hospitals creating an important opportunity to generate insights to these conditions and these medications

Implications of all of the available evidence Our study offers insights into future risk mitigation strategies and SARS-CoV-2 vaccination priorities for individuals with IMIDs, as it highlights that those with IMIDs and those taking rituximab may be at risk of severe COVID-19 outcomes. Critically, our study does not show a link between most targeted immune modifying medications compared to standard systemics and severe COVID-19 outcomes. However, the increased risk of adverse COVID-19 outcomes that we saw in people with IMIDs and those treated with rituximab merits further study.

Competing Interest Statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare the following: BG has received research funding from Health Data Research UK (HDRUK), the Laura and John Arnold Foundation, the Wellcome Trust, the NIHR Oxford Biomedical Research Centre, the NHS National Institute for Health Research School of Primary Care Research, the Mohn-Westlake Foundation, the Good Thinking Foundation, the Health Foundation, and the World Health Organisation; he also receives personal income from speaking and writing for lay audiences on the misuse of science. IJD has received unrestricted research grants and holds shares in GlaxoSmithKline (GSK). CS received departmental research funding from AbbVie, Boehringer Ingelheim, Glaxo SmithKline, Leo, Pfizer, Novartis, Regeneron, SwedishOrphan Biovitrum AB, and Roche and is an investigator within consortia that have industry partners (see biomap.eu and psort.org.uk). JG has received honoraria from Abbvie, Amgen, Celgene, Chugai, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sobi, and UCB, and has research funding from Amgen, Aztra-Zeneca, Gilead, Janssen, Medicago, Novovax and Pfizer. MY has received honoraria from AbbVie and UCB. CWL has received honoraria from Abbvie, Celltrion, Ferring, Galapagos, Gilead, GSK, Iterative Scopes, Janssen, Pfizer and Takeda.

Funding Statement

TPP and NECS CSU provided technical expertise and data infrastructure centre pro bono in the context of a national emergency. This work was supported by the Medical Research Council MR/V015737/1. BGs work on better use of data in healthcare more broadly is currently funded in part by: NIHR Oxford Biomedical Research Centre, NIHR Applied Research Collaboration Oxford and Thames Valley, the Mohn-Westlake Foundation, NHS England, and the Health Foundation; all DataLab staff are supported by BGs grants on this work. LS reports grants from Wellcome, MRC, NIHR, UKRI, British Council, GSK, British Heart Foundation, and Diabetes UK outside this work. JB is funded by a studentship from GSK. AS is employed by LSHTM on a fellowship sponsored by GSK. KB holds a Sir Henry Dale fellowship jointly funded by Wellcome and the Royal Society. HIM is funded by the National Institute for Health Research (NIHR) Health Protection Research Unit in Immunisation, a partnership between Public Health England and LSHTM. AYSW holds a fellowship from BHF. EW holds grants from MRC. ID holds grants from NIHR and GSK. RM holds a Sir Henry Wellcome Fellowship funded by the Wellcome Trust. HF holds a UKRI fellowship. RME is funded by HDR-UK and the MRC. SML was supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (205039/Z/16/Z). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funders. SML was also supported by Health Data Research UK (Grant number: LOND1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust. SML is an investigator on the European Union Horizon 2020-funded BIOMAP Consortium (http://www.biomap-imi.eu/). CS acknowledges support for this research from the NIHR Biomedical Research Centre (BRC) at Kings College London and Guys and St Thomas NHS Foundation Trust and the Psoriasis Association. CWL is funded by a UKRI Future Leaders Fellowship. The views expressed are those of the authors and not necessarily those of the NIHR, NHS England, Public Health England or the Department of Health and Social Care. Funders had no role in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision, submit the article for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Health Research Authority (REC Reference 20/LO/0651) and by the LSHTM Ethics Board (Reference 21863).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Joint first authors

  • ↵** Joint last authors

  • This version of the manuscript has been revised to update figures 2 and 3.

Data Availability

NHS England is the data controller; TPP is the data processor; and the key researchers on OpenSAFELY are acting on behalf of NHS England. This implementation of OpenSAFELY is hosted within the TPP environment which is accredited, the ISO 27001 information security standard and is NHS IG Toolkit compliant; patient data has been pseudonymised for analysis and linkage using industry standard cryptographic hashing techniques; all pseudonymised datasets transmitted for linkage onto OpenSAFELY are encrypted; access, the platform is via a virtual private network (VPN) connection, restricted, a small group of researchers; the researchers hold contracts with NHS England and only access the platform, initiate database queries and statistical models; all database activity is logged; only aggregate statistical outputs leave the platform environment following best practice for anonymisation of results such as statistical disclosure control for low cell counts. The OpenSAFELY research platform adheres, the obligations of the UK General Data Protection Regulation (GDPR) and the Data Protection Act 2018. In March 2020, the Secretary of State for Health and Social Care used powers under the UK Health Service (Control of Patient Information) Regulations 2002 (COPI), require organisations, process confidential patient information for the purposes of protecting public health, providing healthcare services, the public and monitoring and managing the COVID-19 outbreak and incidents of exposure; this sets aside the requirement for patient consent. Taken together, these provide the legal bases, link patient datasets on the OpenSAFELY platform. GP practices, from which the primary care data are obtained, are required, share relevant health information, support the public health response, the pandemic, and have been informed of the OpenSAFELY analytics platform.

https://github.com/opensafely/immunosuppressant-meds-research

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 06, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platform
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platform
Brian MacKenna, Nicholas A. Kennedy, Amir Mehkar, Anna Rowan, James Galloway, Kathryn E. Mansfield, Katie Bechman, Julian Matthewman, Mark Yates, Jeremy Brown, Anna Schultze, Sam Norton, Alex J. Walker, Caroline E Morton, David Harrison, Krishnan Bhaskaran, Christopher T. Rentsch, Elizabeth Williamson, Richard Croker, Seb Bacon, George Hickman, Tom Ward, Simon Davy, Amelia Green, Louis Fisher, William Hulme, Chris Bates, Helen J. Curtis, John Tazare, Rosalind M. Eggo, David Evans, Peter Inglesby, Jonathan Cockburn, Helen I. McDonald, Laurie A. Tomlinson, Rohini Mathur, Angel YS Wong, Harriet Forbes, John Parry, Frank Hester, Sam Harper, Ian J. Douglas, Liam Smeeth, Charlie W Lees, Stephen JW Evans, Ben Goldacre, Catherine Smith, Sinéad M. Langan
medRxiv 2021.09.03.21262888; doi: https://doi.org/10.1101/2021.09.03.21262888
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platform
Brian MacKenna, Nicholas A. Kennedy, Amir Mehkar, Anna Rowan, James Galloway, Kathryn E. Mansfield, Katie Bechman, Julian Matthewman, Mark Yates, Jeremy Brown, Anna Schultze, Sam Norton, Alex J. Walker, Caroline E Morton, David Harrison, Krishnan Bhaskaran, Christopher T. Rentsch, Elizabeth Williamson, Richard Croker, Seb Bacon, George Hickman, Tom Ward, Simon Davy, Amelia Green, Louis Fisher, William Hulme, Chris Bates, Helen J. Curtis, John Tazare, Rosalind M. Eggo, David Evans, Peter Inglesby, Jonathan Cockburn, Helen I. McDonald, Laurie A. Tomlinson, Rohini Mathur, Angel YS Wong, Harriet Forbes, John Parry, Frank Hester, Sam Harper, Ian J. Douglas, Liam Smeeth, Charlie W Lees, Stephen JW Evans, Ben Goldacre, Catherine Smith, Sinéad M. Langan
medRxiv 2021.09.03.21262888; doi: https://doi.org/10.1101/2021.09.03.21262888

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (110)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8987)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1958)
  • Geriatric Medicine (190)
  • Health Economics (402)
  • Health Informatics (1329)
  • Health Policy (660)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10808)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1830)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (999)
  • Ophthalmology (298)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (580)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1903)
  • Public and Global Health (4123)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (549)
  • Rheumatology (225)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (81)